EGFR and neoplasm: According to the National Comprehensive Cancer Network (NCCN) guidelines, patients with EGFR‐mutant disease (mainly the EGFR exon 19 deletion and p.L858R point mutation) are advised to undergo EGFR‐tyrosine kinase inhibitor (TKI) therapy as first‐line treatment.4 It is therefore important to identify the tumor genotype after histopathological determination.